Baxter 2021 Corporate Responsibility Report 11 Corporate Responsibility Commitment 2030 Corporate Responsibility Goals Empower Our Patients Protect Our Planet Appendix Champion Our People and Communities Introduction Cross-Cutting Commitments Stakeholder Engagement Baxter collaborates with a broad range of stakeholders to inform our 2030 Corporate Responsibility Commitment and Goals. We routinely engage with our primary stakeholder groups to assess the ESG issues that are most relevant to our business. We also periodically conduct in-depth materiality assessments to better understand the relative importance of a broad range of ESG issues to our business and stakeholders. Stockholder Outreach As part of the company’s corporate governance outreach program, members of Baxter’s management team and members of the Board, including the company’s Lead Independent Director, engage with investors on a range of topics. In the fall of 2021, the company engaged in discussions with stockholders representing approximately 30% of the company’s outstanding shares (calculated as of Dec. 31, 2021). Topics discussed with stockholders in 2021 included company strategy and performance (including the company’s response to the ongoing COVID-19 pandemic), the proposed Hillrom acquisition (which was completed on Dec. 13, 2021), corporate governance matters (including Board composition, diversity and refreshment and proposed changes to the company’s Certificate of Incorporation to adopt written consent), the Board’s leadership structure, executive compensation and corporate responsibility initiatives (including the company’s 2030 Corporate Responsibility Goals). Stockholder feedback was shared with the full Board and relevant committees. Materiality To understand and prioritize issues that are critical to the long-term sustainability of our business and most relevant to our stakeholders, we periodically conduct materiality assessments. These analyses (which may differ from those conducted for financial statement or other disclosure purposes) inform our corporate responsibility strategy, commitment and goals. See a list of our material corporate responsibility issues (as defined during our 2018 assessment) and their impacts across our value chain. For more information about the process we undertook and the key findings of that assessment, see page 6 of our 2018 Corporate Responsibility Report. As a result of the Hillrom acquisition, Baxter plans to undertake a materiality assessment in 2022 to help ensure the company’s corporate responsibility focus continues to align with the interests of the company and its stakeholders. We will include the results of this analysis in our next corporate responsibility report. BAXTER’S PRIMARY STAKEHOLDER GROUPS Payers Regulators/ policymakers Suppliers Patients Communities Customers Employees Healthcare providers Investors NGOs